Pfizer, a publicly owned company headquartered in the US, was founded in 1849. The company employs approximately 100,900 people and specializes in pharmaceutical manufacturing.
On May 2, 2026, the U.S. Food and Drug Administration (FDA) approved Pfizer and Arvinas' breast cancer drug, branded Veppanu, for adults with advanced estrogen receptor-positive HER2-negative breast cancer whose tumors carry a specific genetic mutation. The pill is authorized for patients whose disease has spread or cannot be removed by surgery. Known as Vepdegestrant, the drug demonstrated a 43% reduction in the risk of disease progression, with a median progression-free survival of 5.0 months compared to 2.1 months for fulvestrant in ESR1-mutant patients. Previously, on May 1, Pfizer announced the FDA accepted a supplemental Biologics License Application for Priority Review regarding a combination treatment for muscle-invasive bladder cancer, utilizing PADCEV alongside Keytruda as a perioperative therapy. Also on May 1, PFA Pension Forsikringsaktieselskab purchased a new $76.83 million stake in Pfizer Inc. during the fourth quarter.
Subscribe for full access to Pfizer's products in full detail
Subscribe for full access to Pfizer's revenue in full detail
Subscribe for full access to Pfizer's products in full detail 
